Gene therapy for carcinoma of the breast

Stoff-Khalili, Mariam A.; Dall, P.; Curiel, David T.

doi:10.1038/sj.cgt.7700929

Cited by 35 publications

(27 citation statements)

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clearly, there remains a need for novel therapeutic strategies for treatment of this disease. A variety of gene therapy approaches for breast cancer treatment have been developed and evaluated, but clinical responses remain poor (2). The majority of these approaches are based on the use of adenoviral vectors to deliver the therapeutic gene or product.…”

Section: Discussionmentioning

confidence: 99%

“…Adenoviral vectors can transduce a variety of cell types, infect both proliferating and quiescent cells, and can be produced in high titers with relative ease. The major barriers to effective therapeutic results are the induction of an immune response (2,3) and the ability to obtain tumor-specific targeting of the vector (4). The use of mammalian cells as systemic delivery vehicles for therapeutic genes has been proposed as a method to overcome rapid adenovirus degradation by the immune system and provide potential for increased delivery doses (5).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Monocyte Chemotactic Protein-1 Secreted by Primary Breast Tumors Stimulates Migration of Mesenchymal Stem Cells

Dwyer

Potter-Beirne²,

Harrington³

et al. 2007

Clinical Cancer Research

389

304

View full text Add to dashboard Cite

Purpose: Major barriers to effective adenovirus-based gene therapy include induction of an immune response and tumor-specific targeting of vectors. The use of mesenchymal stem cells (MSC) as systemic delivery vehicles for therapeutic genes has been proposed as a result of their combined ability to home in on the tumor site and evade the host immune response. This study is aimed at investigating factors mediating homing of human MSCs to breast cancer primary cultures and cell lines in vitro and in vivo. Experimental Design: Fluorescently labeled MSCs were given to mice bearing breast cancer xenografts, and tumor tissue was harvested to detect MSC engraftment. MSC migration in response to primary breast tumors in vitro was quantified, and chemokines secreted by tumor cells were identified. The role of monocyte chemotactic protein-1 (MCP-1) in cell migration was investigated using antibodies and standards of the chemokine. Serum MCP-1 was measured in 125 breast cancer patients and 86 healthy controls. Results: Engrafted MSCs were detected in metastatic breast tumors in mice after systemic administration. There was a significant increase in MSC migration in response to primary breast tumor cells in vitro (6-fold to 11-fold increase). Tumor explants secreted a variety of chemokines including GROa, MCP-1, and stromal cell^derived factor-1a. An MCP-1antibody caused a significant decrease (37-42%) in MSC migration to tumors. Serum MCP-1 levels were significantly higher in postmenopausal breast cancer patients than age-matched controls (P < 0.05).Conclusions: These results highlight a role for tumor-secreted MCP-1in stimulating MSC migration and support the potential of these cells as tumor-targeted delivery vehicles for therapeutic agents.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Monocyte Chemotactic Protein-1 Secreted by Primary Breast Tumors Stimulates Migration of Mesenchymal Stem Cells

Dwyer

Potter-Beirne²,

Harrington³

et al. 2007

Clinical Cancer Research

389

304

View full text Add to dashboard Cite

show abstract

“…Damage to DNA in its biological environment has been associated with alterations in DNA sequence, aberrant gene expression, increased mutation rates, cell transformation and development of cancer [63][64][65]. Interactions of DNA with chemical or physical agents occurring in the environment may result in changes of the genetic information (mutations) and subsequently in serious health disorders [63][64][65].…”

Section: Gold Nanoparticle Based Fret Asssay For the Detection Of Dnamentioning

confidence: 99%

Gold Nanoparticle Based FRET for DNA Detection

et al. 2007

View full text Add to dashboard Cite

The nanoscience revolution that sprouted throughout the 1990s is having great impact in current and future DNA detection technology around the world. In this review, we report our recent progress on gold nanoparticle based fluorescence resonance energy transfer assay to monitor DNA hybridization as well as the cleavage of DNA by nucleases. We tried to discuss a reasonable account of the science and the important fundamental work carried out in this area. We also report the development of a compact, highly specific, inexpensive and user-friendly optical fiber laser-induced fluorescence sensor based on fluorescence quenching by nanoparticles to detect singlestrand DNA hybridization at femtomolar level.

show abstract

“…Because of a deletion in E1B, the 55-kDa E1B protein is not expressed and the mutant adenovirus, termed ONYX-015 [83] , is able to replicate only in wt-p53 deficient cells. The E1B55K-defective adenovirus ONYX-015 is a prototype [73,82,83] of oncolytic viruses and can selectively replicate in and kill p53-deficient HCC cells, the success of cancer gene therapy is not promising unless it is carefully designed based on the biology of a specific [84] tumor type. To enhance the efficiency of such oncolytic viruses, another E1B 55kDa-deficient adenovirus armed with a mouse endostatin gene has been constructed for antitumor activities against HCC, and termed as CNHK200-mE [85] .…”

Section: Oncolytic Virusesmentioning

confidence: 99%

p53 gene in treatment of hepatic carcinoma:Status quo

Guan

La²,

Yang³

et al. 2007

WJG

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the 10 most common cancers worldwide. There is no ideal treatment for HCC yet and many researchers are trying to improve the effects of treatment by changing therapeutic strategies. As the majority of human cancers seem to exhibit either abnormal p53 gene or disrupted p53 gene activation pathways, intervention to restore wild-type p53 (wt-p53) activities is an attractive anti-cancer therapy including HCC. Abnormalities of p53 are also considered a predisposition factor for hepatocarcinogenesis. p53 is frequently mutated in HCC. Most HCCs have defects in the p53-mediated apoptotic pathway although they

show abstract

Gene therapy for carcinoma of the breast

Cited by 35 publications

References 164 publications

Monocyte Chemotactic Protein-1 Secreted by Primary Breast Tumors Stimulates Migration of Mesenchymal Stem Cells

Monocyte Chemotactic Protein-1 Secreted by Primary Breast Tumors Stimulates Migration of Mesenchymal Stem Cells

Gold Nanoparticle Based FRET for DNA Detection

p53 gene in treatment of hepatic carcinoma:Status quo

Contact Info

Product

Resources

About